The U.S. Department of Health and Human Services issued policy guidance allowing licensed pharmacies and physicians to temporarily compound six experimental peptides without federal enforcement action. The policy centers on compounds that include BPC-157 and TB-500. The move comes despite objections raised by FDA career scientists, who argued that evidence on safety and effectiveness remains limited. The policy framing effectively creates a near-term regulatory runway for compounding of these products while standard evidence-generation questions remain unresolved. For biotech and clinical stakeholders, the decision raises immediate issues around quality controls, risk management, and how off-label/experimental compounds intersect with FDA’s typical enforcement posture.